Kane Biotech Inc
Research Kane Biotech Inc (KNE) on Bullrun: market cap CAD 6.15M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKNE
- ExchangeV
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCAD
- Market capCAD 6.15M
- Financial periodQ1 2026
- RevenueCAD 43.22K
- Net income-CAD 714.83K
- Free cash flow-CAD 498.54K
- Gross margin-9.0%
Valuation Snapshot
latest market cap is CAD 6.15M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 427.87K | -CAD 2.72M | -CAD 3.38M | -0.1% | n/a | CAD 901.70K | CAD 2.30M | -CAD 746.55K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | CAD 6.15M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CAD.
About Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kane Biotech Inc's market cap?
Kane Biotech Inc's market capitalization is CAD 6.15M.
What does Kane Biotech Inc do?
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections.